Pharmaceutical

ConSynance wins FDA designation for Prader-Willi syndrome therapy

A Phase II study for ConSynance’s triple monoamine reuptake inhibitor CSTI-500 is slated to begin in 2025.

Jul 26, 2024 - 04:00
ConSynance wins FDA designation for Prader-Willi syndrome therapy
A Phase II study for ConSynance’s triple monoamine reuptake inhibitor CSTI-500 is slated to begin in 2025.
Read the original article

Tags:

Previous Article

Sandoz launches ustekinumab biosimilar in Europe 

Next Article

FDA agrees wider use of BioMarin’s BRINEURA for CLN2

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

PRO-1107 by ProfoundBio Suzhou for Solid Tumor: Likelih...

Apr 21, 2024

FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosimilar

FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosim...

Jul 24, 2024

STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access

STAT+: Pharmalittle: U.S. to impose inflation penalties...

Dec 15, 2023